KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives

KALA BIO, Inc.

Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.
Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).
Company preserving cash while exploring strategic alternatives.

item 2.05 item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-096071
form_type: 8-K/A
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2025-10-02T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.494512+00:00
generated_at: 2026-05-17T04:55:21.282685+00:00
sec_items: ["2.05", "5.02", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-096071
json_url: https://secwatch.observer/filing/0001104659-25-096071.json
markdown_url: https://secwatch.observer/filing/0001104659-25-096071.md
text_url: https://secwatch.observer/filing/0001104659-25-096071.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/0001104659-25-096071-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/tm2527808d1_8ka.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-096071

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.